Drospirenone
Highest phase reached
Approved
Drug type
Small molecule
First approval year
2001
- First approval year
- 2001
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Drospirenone
- Molecular weight
- 366.5
- Structure (SMILES)
- C[C@]12CCC(=O)C=C1[C@@H]1C[C@@H]1[C@H]1[C@@H]3[C@@H]4C[C@@H]4[C@@]4(CCC(=O)O4)[C@@]3(C)CC[C@@H]12
- drospirenone component of angeliq
- Drospirenone component of angeliq
- drospirenone component of beyaz
- Drospirenone component of beyaz
- drospirenone component of nextstellis
- Drospirenone component of nextstellis
- drospirenone component of safyral
- Drospirenone component of safyral
- drospirenone component of yasmin
- Drospirenone component of yasmin
- drospirenone component of yaz
- Drospirenone component of yaz
- slynd
- Slynd
- (6R,7R,8R,9S,10R,13S,14S,15S,16S,17S)-1,3',4',6,6A,7,8,9,10,11,12,13,14,15,15A,16-HEXADECAHYDRO-10,13-DIMETHYLSPIRO-(17H-DICYCLOPROPA(6,7:15,16)CYCLOPENTA(A)PHENANTHRENE-17,2'(5'H)-FURAN)-3,5'(2H)-DIONE
- 0 25mg drsp 0 5mg e2 bay86 4891
- 17 hydroxy 6β 7β 15β 16β dimethylene 3 oxo 17α pregn 4 ene 21 carboxylic acid γ lactone
- 17-Hydroxy-6β,7β:15β,16β-dimethylene-3-oxo-17α-pregn-4-ene-21-carboxylic acid, γ-lactone
- 6r 7r 8r 9s 10r 13s 14s 15s 16s 17s 1 3 4 6 6a 7 8 9 10 11 12 13 14 15 15a 16 hexadecahydro 10 13 dimethylspiro 17h dicyclopropa 6 7 15 16 cyclopenta a phenanthrene 17 2 5 h furan 3 5 2h dione
- angeliq component drospirenone
- ANGELIQ COMPONENT DROSPIRENONE
- beyaz component drospirenone
- BEYAZ COMPONENT DROSPIRENONE
- drospirenona
- Drospirenona
- drospirenone
- Drospirenone
- DROSPIRENONE [EP MONOGRAPH]
- drospirenone [INN]
- DROSPIRENONE [JAN]
- DROSPIRENONE [MART.]
- DROSPIRENONE [MI]
- DROSPIRENONE [ORANGE BOOK]
- DROSPIRENONE [USAN]
- DROSPIRENONE [USP MONOGRAPH]
- DROSPIRENONE [USP-RS]
- DROSPIRENONE [VANDF]
- Drospirenone [WHO-DD]
- Drospirenone 4 MG
And 30 more, listed on the interactive page.
- ATC classification codes
- G03AC10
Sources for recorded values
- CAS registry numbers
- 67392-87-4
- ChEMBL ID
- CHEMBL1509
- InChIKey
- METQSPRSQINEEU-HXCATZOESA-N
- PubChem compound IDs
- 68873
- RxNorm IDs (RxCUI)
- 11636
- FDA ingredient codes (UNII)
- N295J34A25
- Applicant
- BAYER HLTHCARE
- Approval date
- 28 Sept 2005
- Application number
- NDA021355
- Patents
- 30
- Designations
- 0
- Earliest recorded loss of exclusivity
- 28 Jun 2031
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Pharmacology name
- drospirenone
- Type
- Synthetic organic
- Drug name stem
- -renone
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
- Mechanism
- Progesterone receptor agonist
- Action type
- Agonist
- Target
- Progesterone receptor
- Protein identifier
- P06401
- Action
- Antagonist
- Action type
- Antagonist
- Target
- Mineralocorticoid receptor
- Gene symbol
- NR3C2
- Protein identifier
- P08235
- Primary target
- Yes
- Mechanism
- Mineralocorticoid receptor antagonist
- Action type
- Antagonist
- Target
- Mineralocorticoid receptor
- Protein identifier
- P08235
- Mechanism
- Progesterone receptor agonist
- Action type
- Agonist
- Target
- Progesterone receptor
- Mechanism
- Mineralocorticoid receptor antagonist
- Action type
- Antagonist
- Target
- Mineralocorticoid receptor
- Action type
- Agonist
- Gene symbol
- PGR
- Protein identifier
- P06401
- Organism
- Homo sapiens
- Target development level
- Clinical
- Action type
- Antagonist
- Gene symbol
- NR3C2
- Protein identifier
- P08235
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Polycystic Ovary Syndrome
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000660
- Subject identifier
- D011085
- Condition
- Obesity
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001073
- Subject identifier
- D009765
- Condition
- Acne Vulgaris
- Highest recorded phase
- 4
- Condition identifier
- EFO:0003894
- Subject identifier
- D000152
- Condition
- Bulimia Nervosa
- Highest recorded phase
- 2
- Condition identifier
- EFO:0005204
- Subject identifier
- D052018
- Condition
- Bulimia
- Highest recorded phase
- 2
- Condition identifier
- EFO:0005924
- Subject identifier
- D002032
- Condition
- Hidradenitis Suppurativa
- Highest recorded phase
- 2
- Condition identifier
- EFO:1000710
- Subject identifier
- D017497
- Condition
- Dysmenorrhea
- Highest recorded phase
- 3
- Condition identifier
- HP:0100607
- Subject identifier
- D004412
- Condition
- Depressive Disorder
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0002050
- Subject identifier
- D003866
- Condition
- Premenstrual Syndrome
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0004169
- Subject identifier
- D011293
- Condition identifier
- EFO_0000195
- Condition identifier
- EFO_0000660
- Highest recorded phase
- 3
- Condition identifier
- EFO_0001065
- Condition identifier
- EFO_0003894
- Condition identifier
- EFO_0009006
- Condition identifier
- EFO_0009520
- Condition identifier
- EFO_0009520
- Highest recorded phase
- 4
- Condition identifier
- EFO_1000710
- Highest recorded phase
- 2
- Condition identifier
- GO_0042697
- Condition identifier
- HP_0000132
- Highest recorded phase
- 1
- Condition identifier
- HP_0000789
- Condition identifier
- HP_0000855
- Condition identifier
- HP_0000858
- Condition identifier
- HP_0001007
- Highest recorded phase
- 2
- Condition identifier
- HP_0001513
- Highest recorded phase
- 3
- Condition identifier
- HP_0002829
- Condition identifier
- HP_0003326
- Condition identifier
- HP_0008209
- Condition identifier
- HP_0012531
- Condition identifier
- HP_0012531
- Highest recorded phase
- 4
- Condition identifier
- HP_0100607
- Condition identifier
- HP_0100607
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0001119
- Condition identifier
- MONDO_0001134
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0002050
And 15 more, listed on the interactive page.
- Event
- bleeding time prolonged
- Reports
- 2
- Reporting signal score
- 7.70076
- Event
- carotid artery thrombosis
- Reports
- 3
- Reporting signal score
- 14.028
- Event
- cerebral venous sinus thrombosis
- Reports
- 2
- Reporting signal score
- 9.0885
- Event
- dyspareunia
- Reports
- 4
- Reporting signal score
- 14.1657
- Event
- electrocardiogram qt interval abnormal
- Reports
- 2
- Reporting signal score
- 9.12609
- Event
- intermenstrual bleeding
- Reports
- 2
- Reporting signal score
- 9.61889
- Event
- menorrhagia
- Reports
- 6
- Reporting signal score
- 13.2714
- Event
- metrorrhagia
- Reports
- 12
- Reporting signal score
- 42.3278
- Event
- oligomenorrhoea
- Reports
- 2
- Reporting signal score
- 7.93574
- Event
- ovarian cancer
- Reports
- 3
- Reporting signal score
- 9.57963
- Event
- pituitary gland operation
- Reports
- 1
- Reporting signal score
- 8.11198
- Event
- postmenopausal haemorrhage
- Reports
- 4
- Reporting signal score
- 16.6657
- Event
- pregnancy on oral contraceptive
- Reports
- 8
- Reporting signal score
- 41.5958
- Event
- psychotic disorder
- Reports
- 10
- Reporting signal score
- 20.6804
- Event
- suppressed lactation
- Reports
- 5
- Reporting signal score
- 26.1898
- Event
- thrombophlebitis superficial
- Reports
- 3
- Reporting signal score
- 9.55389
- Event
- urticaria localised
- Reports
- 2
- Reporting signal score
- 13.0791
- Event
- uterine polyp
- Reports
- 2
- Reporting signal score
- 7.55753
- Event
- vaginal haemorrhage
- Reports
- 5
- Reporting signal score
- 8.89585
- NCT00089414
- NCT00569244
- NCT00651469
- NCT00656981
- NCT00722761
- NCT00818519
- NCT00722800
- NCT00948402
- NCT01581814
- NCT04278755
- NCT06039826
- Route
- Oral
- How often
- Once daily
- Preferably after evening meal or at bedtime
- Take in the same order on the blister pack
- Take without regard to meals
- Hydrogen bond acceptors
- 3
- Hydrogen bond donors
- 0
- Polar surface area
- 43.37
- Calculated partition coefficient (ALogP)
- 4.31
- Calculated partition coefficient (XLogP)
- 3.5
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 0
- Heavy atoms
- 27
- Molecular formula
- C24H30O3
- Monoisotopic mass
- 366.21949481
- Natural product
- Yes
- 50419-482
- 50419-483
- Recorded assays
- 903
- Active assays
- 57
- Confirmatory
- Other
- Screening
- Summary
- Mineralocorticoid Receptor Antagonists
Oral bioavailability
- Median
- 76
- Mean
- 76
- Minimum
- 76
- Maximum
- 76
- Unit
- %
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- F
Related records
Trials (95)
- "E4/DRSP Endocrine Function, Metabolic Control and Hemostasis Study"
- "Quick-starting" of a New Combined Hormonal Contraceptive Pills, 15 mg Estetrol/3 mg Drospirenone VS 20 mcg Ethinylestradiol/75 mcg Gestodene Focusing on Ovulation Inhibition
- A Drug-Drug Interaction Study Between HS-10374 Tablets and Drospirenone and Ethinyl Estradiol Tablets(Yasmin®)
- A Drug-drug Interaction Study of Vorasidenib and a Combined Oral Contraceptive in Healthy Female Participants
- A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies
- A Randomized Feasibility Trial Comparing Drospirenone and Norethindrone for Postpartum Hypertension Management in Preeclampsia
- A Study in Healthy Female Participants to Investigate the Effect of JNJ-56136379 at Steady-state on the Single-dose Pharmacokinetics of Ethinylestradiol and Drospirenone (Oral Contraceptive) and on the Single-dose Pharmacokinetics of Midazolam (Probe Substrate for Cytochrome P450 3A4)
- A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese
- A Study of Milvexian in Healthy Adult Females
- A Study to Evaluate Inhibition of Ovulation of Two Oral Estrogen/Progestogen Regimens in Healthy, Young Females Over a Period of 3 Treatment Cycles
- A Study to Evaluate Ovarian Follicular Activity and Hormone Levels for DR-102 Compared to Two 28-Day Oral Contraceptives
- A Study to Evaluate the Effectiveness of NuvaRing® to Prevent Pregnancies in Chinese Women (P06450)
- A Study to Examine the Safety and Efficacy of Drospirenone and Ethinyl Estradiol (YAZ) Versus Placebo In HS
- A Study to Investigate the Effects of BMS-986278 on Drospirenone and Ethinyl Estradiol Drug Levels in Healthy Female Participants
- A Study to Investigate the Interaction Between JNJ-64155806 and Ethinylestradiol/Drospirenone in Healthy Females
- Aspirin for the Management of Endometriosis-associated Pelvic Pain
- Assess Satisfaction of Patients and Physicians With Results of Yaz Plus Treatment for 13 Cycles
- Assessment of the Pharmacodynamic Effect on Plasma Folate and Red Blood Cell Folate and Comparison of the Folate Metabolites During the 24 Weeks of Treatment (Yasmin + Metafolin Versus Yasmin + Folic Acid) Followed by a 20 Week Elimination Phase of Folate
- Binge Eating & Birth Control
- Can Drospirenone be Used to Prevent LH Surge in Controlled Ovarian Stimulation in PCOS?!
Approved for (1)
In development for (8)
- Binge eating disorder Phase 2
- Bulimia nervosa Phase 2
- Depressive disorder Phase 2
- Dysmenorrhea Phase 3
- Hidradenitis suppurativa Phase 2
- Obesity disorder Phase 1
- Polycystic ovary syndrome Phase 3
- Premenstrual tension Phase 2
Other linked conditions (2)
- Adenomyosis
- Endometriosis